Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tocilizumab by F. Hoffmann-La Roche for Non-Small Cell Lung Cancer: Likelihood of Approval
Tocilizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Small Cell Lung Cancer. According...
Tocilizumab by F. Hoffmann-La Roche for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Tocilizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Diffuse Large B-Cell Lymphoma. According...
Tocilizumab by Chugai Pharmaceutical for Follicular Lymphoma: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
Tocilizumab by Chugai Pharmaceutical for Sepsis: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Sepsis. According to GlobalData, Phase II...
Tocilizumab by Chugai Pharmaceutical for Septic Shock: Likelihood of Approval
Tocilizumab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Septic Shock. According to GlobalData, Phase...